Precision NanoSystems specializes in the development and manufacturing of mRNA lipid nanoparticles and nanomedicine technologies. Self-described applications include genomic medicine, vaccines, gene therapy, and drug delivery services.

Precision NanoSystems

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Metric
Company Name	Precision NanoSystems	Sutro Biopharma, Inc.
Symbol		STRO
MSH ID	COM:PRECISIONNANOSYSTEMS	COM:SUTROBIO
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	CA	US
Stage		Post-IPO Equity
Employee Count		300
Website	precisionnanosystems.com	sutrobio.com
LinkedIn
Founders

Metric
Market Cap		294.46M
Enterprise Value
Monthly Web Traffic	3.56K	9.82K
Web Traffic Growth	0.38	0.04
Valuation
Raised Capital	18.20M	75M

Metric
Revenue		153.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit		146.91M
EBITDA		-82.46M
Operating Income		-89.28M
Net Income		-106.79M
EPS		-1.78
Diluted EPS		-1.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.96
Operating Profit Margin		-0.58
EBITDA Margin		-0.54
Net Profit Margin		-0.69
Return on Equity		-0.71
Return on Assets		-0.23
Return on Capital Employed		-0.24

COM:PRECISIONNANOSYSTEMS

Precision NanoSystems

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-1.56
P/B Ratio		2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		4.33
EV Multiple		-1.22

Metric
Days Sales Outstanding		124.77
Days Payables Outstanding
Days Inventory Outstanding		0.00
Operating Cycle		124.77
Cash Conversion Cycle		-111.15
Asset Turnover		0.38

Metric
Operating Cash Flow		-111.62M
Free Cash Flow		-115.93M
Cash Flow to Debt		-0.44
Operating Cash Flow/Sales		-0.44
Free Cash Flow Yield		-0.57

Metric
Cash & Equivalents		69.27M
Accounts Receivable		-28.96M
Inventory
Goodwill
Debt to Capitalization		0.62
Debt to Assets		0.09
Current Ratio		5.18
Quick Ratio		5.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.50
R&D to Revenue		3.49
SG&A to Revenue		1.24